The study sponsored by the Icahn School of Medicine at Mount Sinai aims to explore the effects of light therapy on sleep, memory, and brain function in patients with Mild Cognitive Impairment (MCI) and Mild Alzheimer's Disease (AD). Given the prevalence of sleep disturbances in these populations, which can affect overall health and cognitive function, successful outcomes could lead to the development of innovative light-delivery methods that address these issues. The potential market for cognitive enhancement therapies in aging populations is significant, particularly as the global prevalence of Alzheimer's disease continues to rise. The findings may position the sponsor favorably within the growing field of non-pharmacological interventions for cognitive disorders, although competition from existing and emerging therapies will need to be monitored closely.